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The financial crisis which has hit Europe (and beyond)
in 2008 has been described as a “health system shock”
by the WHO which has urged EU Member States to
ensure that the national healthcare systems would con-
tinue to promote universal access to health services by
increasing efficiency in the health sector.
The challenge for Member States is to ensure access
to innovative medicines for unmet medical needs, while
at the same time meeting cost containment objectives
and rewarding innovation.
The need for improving sustainability of EU health
systems has led to thorough analysis of different pricing
models in Europe which showed substantial support of
a wide range of stakeholders (including research-based
industry, patients and payers) in favour of a differential
pricing system as a reimbursement policy measure for
new and cost-intensive medicinal products, which is the
case for most orphan medicinal products (OMPs).
One way to reduce the impact of OMPs on national
healthcare budgets is to differentiate prices according to
different levels of Gross Domestic Products (GDPs) and
introduce some sense of proportionality between a
country’s ability to pay and a fair level of reward for
innovation.
The idea for this differential pricing system would
therefore be to introduce a price differentiation not
country by country but by “clusters of countries”: High,
Medium and Low income countries, knowing that in
Europe the GDP per capita varies from 1 to 6, with Lux-
embourg being the highest and Bulgaria the lowest.
In a first phase, differential pricing would be limited to
medicinal products responding to high unmet medical
need: a price would be agreed on the basis of a value-
based pricing system, with the value being assessed with
the EU Transparent Value Framework delivered by the
MoCA (Mechanism of coordinated Access) process.
Then variations by cluster would apply within a range
from minus to plus 10%.
Two main obstacles to the introduction of a differen-
tial pricing system have been identified as being the
External Reference Pricing and the practice of parallel
imports.
The reflection process is still on-going at EU level on
differential pricing as a way to address the three following
main policy objectives: timely and equitable access to
medicinal products for all patients, control of health
expenditures linked to medicines and reward for innova-
tion. There is an overall need for political support from
Member States and industry.
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